Gekko Brief
AI summaryNov 9 close
Scholar Rock advances the commercialization of ISEMBLYD for spinal muscular atrophy, with plans for a 50-country rollout, alongside a reported year-on-year revenue drop and no current profits. Management is also set to speak at the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference in London on 16 and 17 November. Separately, coverage this week noted shares near $43.98 with a market cap of $5.23 billion as of 3 November, ahead of the move described below.
Shares close at $51.55, up 9.8%, sitting between the 50-day average of $47.01 and the 200-day average of $48.22. The stock's one-month return stands at 22.2%, though the three-month return is -1% and the six-month return is 6.6%; the one-year return is 79%. The GekkoIndex reads 44.4, placing SRRK in the Distribution zone, down from a five-day change of -15. Gekko Fair Value is set at $52.21, putting the current price 1.3% below that level.
Scholar Rock reports earnings on 10 November 2026 before the open, zero days away, falling inside a typical 20-trading-day holding window; the prior print on 6 August 2026 produced a 10.5% reaction, against an average absolute reaction of 8.5% across prior reports. Over the last 90 days, insiders made 4 open-market purchases totaling $11,937,192. Seasonality from this calendar point shows a 22.4% average 20-day return across 5 years, with gains in 3 of them. Analyst coverage includes 15 buy ratings, 1 hold and 0 sell among 16 firms, with a consensus target of $70.44.